**4-year surveillance (2017) –** [**Psychosis and schizophrenia in adults**](https://www.nice.org.uk/guidance/cg178/) **(2014) NICE guideline CG178**

**Stakeholder consultation comments form - proposal for ‘no update’**

Consultation on the proposal for ‘no update’ opens on: 9am 15 August 2017

Comments on proposal to be submitted: no later than 9am 4 September 2017

|  |  |
| --- | --- |
| **Please enter the name of your registered stakeholder or respondent organisation below.**  Please use this form for submitting your comments to NICE.   1. Please put each new comment in a new row. 2. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline. 3. If you wish to draw our attention to published studies, please supply the full reference. 4. NICE is unable to accept comments from non-registered organisations. If you wish your comments to be considered please register via the NICE website or contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/cg178/documents/stakeholder-list-2) that most closely represents your interests and pass your comments to them. | |
| Organisation name – Stakeholder or respondent  (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank): |  |
| Disclosure  Please disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry. |  |
| Name of commentator: |  |

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

| **ID** | **Questions** | **Overall response**  yes / no | **Comments**  Please insert each new comment in a new row |
| --- | --- | --- | --- |
| 1 | Do you agree with the proposal not to update the guideline? |  |  |
| 2 | We have identified evidence which indicates that cognitive behavioural therapy (CBT) may not be effective for the treatment of negative symptoms of psychosis and schizophrenia. Does this concur with observations in clinical practice? |  |  |
| 3 | How often are arts therapies offered to, and taken up, by people with psychosis and schizophrenia in the UK? What clinical observations can be made about the effectiveness of these treatments? | N/A |  |
| 4 | In practice, which pharmacological treatment options are given to people with schizophrenia or psychosis who are in remission? | N/A |  |
| 5 | Currently, recommendation 1.3.5.1 recommends that the choice of antipsychotic should be made by the service user and healthcare professional together, through discussion of the benefits and a number of listed potential side effects. In practice, does this recommendation provide appropriate guidance, or if appropriate according to the evidence available, would more specific guidance on the choice of drug in specific circumstances be welcomed? |  |  |
| 6 | **Do you agree with the proposal to remove the research recommendation:**  What are the short- and long-term benefits to physical health of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks? |  |  |
| 7 | Do you have any comments on areas excluded from the scope of the guideline? |  |  |
| 8 | Do you have any comments on equalities issues? |  |  |

**Please email this form to:** [**surveillance@nice.org.uk**](mailto:surveillance@nice.org.uk)

**Closing date: 9am Monday 4 September 2017**

**PLEASE NOTE:**

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.